Immuneering Corp (IMRX) income statement
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30
$3.50+0.04 (+1.16%)
Close on Nov 18, 2026Market cap $226.67MP/E –Yield –
Immuneering Corp income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -43.1%
Financial strength
- Current ratio
- 13.97
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 539.6%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.34
- Dividend yield
- –
See a number that looks wrong?